Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T14:17:00.702Z.
Calculation as of: 2026-10-06T14:17:00.702Z.
Quote observation: 2026-10-06T14:15:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 934548bd97ab8c390298f716fcf622fc2d1107cfab085c47b2b47650fd31fbc6
EARNINGS YIELD
N/A
Market Cap
$666.04M
Earnings Yield
0.88%
TTM Avg
4.56%
3Y Avg
4.76%
5Y Avg
4.76%
Market Cap
$646.50M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$615.44M
Earnings Yield
N/A
TTM Avg
25.29%
3Y Avg
18.23%
5Y Avg
18.23%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Helus Pharma Inc. (HELP) | $659.20M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $666.04M | 0.88% | 4.56% | 4.76% | 4.76% |
| Annexon, Inc. (ANNX)vs › | $667.66M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $646.50M | N/A | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $678.37M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $635.14M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $623.31M | N/A | N/A | N/A | N/A |
| AngioDynamics, Inc. (ANGO)vs › | $620.81M | N/A | 2.32% | 2.32% | 1.62% |
| Fulgent Genetics, Inc. (FLGT)vs › | $615.44M | N/A | 25.29% | 18.23% | 18.23% |
| Anteris Technologies Global Corp. (AVR)vs › | $708.82M | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute